Workflow
BCHT(688276)
icon
Search documents
百克生物(688276) - 关于长春百克生物科技股份公司非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
2025-04-20 13:45
关于长春百克生物科技股份公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 根据中国证券监督管理委员会发布的《上市公司监管指引第 8 号——上市 公司资金往来、对外担保的监管要求》(证监会公告[2022]26 号)和上海证券 交易所发布的《上海证券交易所上市公司自律监管指南第 2 号——业务办理》 《科创板上市公司自律监管指南第 7 号——年度报告相关事项》的规定,就百 克生物编制的 2024 年度非经营性资金占用及其他关联资金往来情况汇总表(以 下简称"汇总表")出具专项说明。 如实编制和对外披露该汇总表,并确保其真实性、合法性及完整性是百克 生物管理层的责任。我们对汇总表所载资料与我们审计百克生物 2024 年度财务 报表时所复核的会计资料和经审计的财务报表的相关内容进行了核对,在所有 重大方面未发现不一致。除了对百克生物实施 2024 年度财务报表审计中所执行 的对关联方交易有关的审计程序外,我们未对汇总表所载资料执行额外的审计 程序。为了更好地理解百克生物 2024 年度控股股东及其他关联方资金占用的情 况,后附的汇总表应当与已审财务报表一并阅读。 本专项说 ...
百克生物(688276) - 长春百克生物科技股份公司募集资金存放与使用情况鉴证报告
2025-04-20 13:45
长春百克生物科技股份公司 募集资金存放与使用情况鉴证报告 大华核字[2025]0011003658 号 大 华 会 计 师 事 务 所 ( 特 殊 普 通 合 伙 ) DaHuaCertified PublicAccountants(SpecialGeneral Partnership) 一、 募集资金存放与使用情况鉴证报告 1-2 二、 长春百克生物科技股份公司 2024 年度募集资 金存放与实际使用情况的专项报告 1-13 大华会计师事务所(特殊普通合伙) 北京市海淀区西四环中路 16 号院 7 号楼 12 层[100039] 电话:86(10)58350011 传真:86(10)58350006 www.dahua-cpa.com 募 集 资 金 存 放 与 使 用 情 况 鉴 证 报 告 大华核字[2025]0011003658 号 长春百克生物科技股份公司 募集资金存放与使用情况鉴证报告 (2024 年度) 目录 页次 长春百克生物科技股份公司全体股东: 我们审核了后附的长春百克生物科技股份公司(以下简称百克生 物公司)《2024 年度募集资金存放与实际使用情况的专项报告》(以 下简称"募集资金专项 ...
百克生物(688276) - 长春百克生物科技股份公司关于召开2024年年度股东会的通知
2025-04-20 13:45
证券代码:688276 证券简称:百克生物 公告编号:2025-019 长春百克生物科技股份公司 关于召开 2024 年年度股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 一、 召开会议的基本情况 (一) 股东会类型和届次 2024 年年度股东会 召开日期时间:2025 年 5 月 13 日 14 点 00 分 召开地点:长春百克生物科技股份公司 5 楼会议室(吉林省长春市卓越大街 138 号) (五) 网络投票的系统、起止日期和投票时间。 网络投票系统:上海证券交易所股东大会网络投票系统 网络投票起止时间:自 2025 年 5 月 13 日 至 2025 年 5 月 13 日 采用上海证券交易所网络投票系统,通过交易系统投票平台的投票时间为股 股东会召开日期:2025年5月13日 本次股东会采用的网络投票系统:上海证券交易所股东大会网络投票系 统 (二) 股东大会召集人:董事会 (三) 投票方式:本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四) 现场会议召开的日期、时间和地 ...
百克生物(688276) - 长春百克生物科技股份公司第六届监事会第二次会议决议的公告
2025-04-20 13:45
长春百克生物科技股份公司 第六届监事会第二次会议决议的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 2025 年 4 月 17 日,长春百克生物科技股份公司(以下简称"公司")第六 届监事会第二次会议以现场会议及通讯方式召开,本次会议由监事会主席冯大强 先生主持,会议应到监事 3 名,实到监事 3 名,符合《中华人民共和国公司法》 和《长春百克生物科技股份公司章程》(以下简称"《公司章程》")规定的法 定人数,本次监事会会议决议合法有效。 二、监事会会议审议情况 经与会监事审议表决,一致通过如下议案: 证券代码:688276 证券简称:百克生物 公告编号:2025-012 (一)审议通过《<2024 年年度报告>全文及摘要》 监事会认为:公司 2024 年年度报告的编制和审议程序符合相关法律法规及 《公司章程》等内部规章制度的规定;公司 2024 年年度报告的内容与格式符合 中国证监会和上海证券交易所的各项规定,所包含的信息能够真实、准确、完整 地反映公司 2024 年度的财务状况和经营成果 ...
百克生物(688276) - 长春百克生物科技股份公司第六届董事会第五次会议决议的公告
2025-04-20 13:45
证券代码:688276 证券简称:百克生物 公告编号:2025-011 长春百克生物科技股份公司 第六届董事会第五次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 2025 年 4 月 17 日,长春百克生物科技股份公司(以下简称"公司")第六 届董事会第五次会议以现场会议及通讯方式召开,本次会议由董事长李秀峰先生 主持,会议应到董事 11 名,实到董事 11 名,符合《中华人民共和国公司法》和 《长春百克生物科技股份公司章程》规定的法定人数,本次董事会会议决议合法 有效。 (二)审议通过《2024 年度利润分配预案》 表决情况:11 票赞成,0 票反对,0 票弃权。 二、董事会会议审议情况 经与会董事审议表决,一致通过如下议案: (一)审议通过《<2024 年年度报告>全文及摘要》 表决情况:11 票赞成,0 票反对,0 票弃权。 本议案已通过公司审计委员会事前审议。 本议案尚需提交股东会审议。 具体内容详见公司于同日在上海证券交易所网站(www.sse.com.cn)披露的 《长 ...
百克生物(688276) - 长春百克生物科技股份公司关于2024年度利润分配预案的公告
2025-04-20 13:45
证券代码:688276 证券简称:百克生物 公告编号:2025-013 长春百克生物科技股份公司 重要内容提示: 每股分配比例:每 10 股派发现金红利人民币 1.69 元(含税),不送红股, 不进行资本公积转增股本。 本次利润分配以实施权益分派股权登记日登记的总股本为基数,具体日 期将在权益分派实施公告中明确。 如在实施权益分派的股权登记日前公司总股本发生变动的,拟维持每股 分配比例不变,相应调整分配总额,并将另行公告具体调整情况。 本次利润分配未触及《上海证券交易所科创板股票上市规则(2024 年 4 月修订)》(以下简称《科创板股票上市规则》)第 12.9.1 条第一款第(八)项规 定的可能被实施其他风险警示的情形。 关于 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 | 项目 | 2024年度 | 2023年度 | 2022年度 | | --- | --- | --- | --- | | 现金分红总额(元) | 69,908,134.06 | 62,048,639.70 | 61 ...
百克生物(688276) - 2025 Q1 - 季度财报
2025-04-20 13:40
Financial Performance - The company's revenue for Q1 2025 was ¥162,290,516.78, a decrease of 39.96% compared to ¥270,288,441.14 in the same period last year[4] - Net profit attributable to shareholders was ¥1,064,275.78, down 98.24% from ¥60,565,065.43 year-on-year[4] - The net profit after deducting non-recurring gains and losses was -¥3,411,965.39, representing a decline of 105.71% compared to ¥59,803,967.25 in the previous year[4] - The company reported a total comprehensive income of -¥3,554,830.30 for Q1 2025, compared to ¥52,979,886.88 in Q1 2024[23] - Basic and diluted earnings per share for Q1 2025 were both ¥0.00, compared to ¥0.15 in Q1 2024[23] - The net loss for Q1 2025 was CNY 2,487,647.36, a significant decline compared to a profit of CNY 65,632,514.01 in Q1 2024[31] - The total comprehensive income for the first quarter of 2025 was CNY -2,588,300.46, contrasting with CNY 54,510,490.93 in the first quarter of 2024[32] Cash Flow - The net cash flow from operating activities was -¥68,805,373.58, worsening from -¥7,933,515.62 in the same period last year[4] - Operating cash flow for Q1 2025 was negative at -¥68,805,373.58, compared to -¥7,933,515.62 in Q1 2024[26] - Cash flow from operating activities for Q1 2025 was CNY -68,809,529.80, compared to CNY -7,939,865.44 in Q1 2024, indicating a worsening cash flow situation[35] - The net cash flow from investing activities was -CNY 123,751,836.25, compared to -CNY 86,292,352.83 in the previous period, indicating a significant increase in cash outflow[27] - Cash inflow from financing activities in Q1 2025 was CNY 71,834,374.47, an increase from CNY 44,415,955.34 in Q1 2024[35] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,352,186,880.18, an increase of 2.83% from ¥5,204,868,837.55 at the end of the previous year[5] - The total liabilities increased to ¥1,137,016,519.35 in the latest report, up from ¥987,120,567.56[20] - The total assets as of March 31, 2025, amounted to CNY 5,652,254,361.52, an increase from CNY 5,503,880,417.19 as of December 31, 2024[31] - The total liabilities increased to CNY 1,134,869,744.86 from CNY 984,884,421.21, reflecting a rise in financial obligations[30] Research and Development - R&D investment totaled ¥36,858,462.61, a decrease of 21.48% from ¥46,940,335.50, while the proportion of R&D investment to revenue increased by 5.34 percentage points to 22.71%[5] - R&D expenses for Q1 2025 were ¥36,858,462.61, down 21.5% from ¥46,940,335.50 in Q1 2024[22] - The company is actively pursuing new product development and clinical trials for innovative vaccines, including a new mRNA tumor vaccine[14] - The company has submitted clinical trial applications for its restructured shingles vaccine and adjuvanted flu vaccine, which have been accepted[14] - The company is expanding its product pipeline, including adult vaccines and mRNA technology, to enhance its core competitiveness[14] Shareholder Information - The total number of common shareholders at the end of the reporting period was 10,054[8] - The largest shareholder, Changchun High-tech Industry (Group) Co., Ltd., holds 41.46% of the shares, totaling 171,488,182 shares[9] - Total equity attributable to shareholders was ¥4,215,170,360.83, slightly down from ¥4,217,748,269.99[20] - The company's total equity decreased slightly to CNY 4,517,384,616.66 from CNY 4,518,995,995.98, reflecting a minor reduction in shareholder value[31] Sales and Marketing - The company reported a decline in sales and net profit due to external factors, including reduced demand for the shingles vaccine, with a focus on optimizing marketing strategies[14] - The company plans to expand its sales channels and increase promotional efforts, which contributed to the rise in sales expenses[6] - Sales expenses in Q1 2025 were ¥73,607,698.35, a decrease of 26.3% from ¥99,954,306.04 in Q1 2024[22] - Cash inflow from sales of goods and services in Q1 2025 was CNY 176,473,731.79, down from CNY 253,656,020.12 in Q1 2024, reflecting a decline of approximately 30.4%[34] Future Outlook - The company plans to implement new accounting standards starting from 2025, which may affect future financial reporting[36]
百克生物(688276) - 2024 Q4 - 年度财报
2025-04-20 13:35
Financial Performance - The company's operating revenue for 2024 was CNY 1,229,084,097.15, a decrease of 32.64% compared to CNY 1,824,688,777.32 in 2023[26]. - Net profit attributable to shareholders for 2024 was CNY 232,093,825.73, down 53.67% from CNY 501,009,182.39 in 2023[26]. - The net profit after deducting non-recurring gains and losses was CNY 229,810,386.80, a decrease of 53.42% compared to CNY 493,358,270.16 in the previous year[26]. - The gross profit margin for the main business is 85.42%, down by 4.82 percentage points from the previous year[105]. - The company reported a 42.50% decrease in non-operating income, mainly due to reduced insurance claims compared to the previous year[105]. - The company achieved total revenue of 1,229.08 million yuan, a decrease of 32.64% compared to the previous year's revenue of 1,824.69 million yuan[102]. - Net profit attributable to the parent company was 232.09 million yuan, down 53.67% from 501.01 million yuan in the same period last year[102]. - The company reported a revenue increase of 15% year-over-year, reaching 1.2 billion yuan in the latest quarter[195]. - The company reported a net profit margin of 18%, reflecting improved operational efficiency[196]. Research and Development - The company is focusing on innovation-driven development, with progress in multiple research products including liquid nasal spray flu vaccine and rabies monoclonal antibody[39]. - The company has 16 major projects under research, with 7 projects in clinical trial approval and registration stages, and R&D investment of CNY 156.14 million, accounting for 12.70% of revenue[40]. - The company is developing multiple vaccines, including a liquid nasal flu vaccine and a recombinant shingles vaccine, with significant progress reported in clinical trials[140]. - The company has established five core technology platforms for vaccine development, including virus large-scale culture technology and mRNA vaccine technology[52]. - The company is committed to continuous R&D investment to maintain its competitive edge and support sustainable growth in the biopharmaceutical industry[61]. - The total R&D expenditure for the year was approximately ¥156.14 million, a decrease of 21.43% compared to the previous year, with R&D expenses accounting for 12.70% of operating revenue, an increase of 1.81 percentage points[70]. - The company is focusing on expanding its product pipeline and enhancing its research capabilities to meet the growing demand for innovative vaccines[57]. - The company has submitted IND applications for multiple vaccines, including the recombinant herpes zoster vaccine and the adjuvant flu vaccine, both of which have received acceptance notifications[75]. - The company is preparing to launch clinical trials for its HSV-2 vaccine, which has received approval for trial applications[142]. Market Strategy and Expansion - The company is actively expanding its international market, with the first exports of the shingles vaccine to Colombia and the chickenpox vaccine to Afghanistan, reaching over 10 countries[43]. - The company is focusing on enhancing its product pipeline in adult vaccines, multi-valent vaccines, and therapeutic vaccines, as well as mRNA technology[87]. - The company is exploring acquisition opportunities to enhance its product portfolio, targeting a potential acquisition valued at 500 million yuan[195]. - The company plans to optimize its marketing system and increase public awareness of related diseases to stimulate user demand[87]. - The company is actively adjusting its marketing strategies in response to market dynamics to achieve high-quality development[39]. - The company aims to enhance its brand recognition and influence through professional marketing strategies and collaborations with academic promotion personnel[53]. - The company plans to increase its marketing budget by 25% to support new product launches and market expansion[199]. Governance and Compliance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not violated any decision-making procedures for providing guarantees[10]. - The company has not faced any issues with the majority of directors being unable to ensure the authenticity, accuracy, and completeness of the annual report[12]. - The company updated 20 governance documents to align with regulatory requirements, enhancing governance transparency and compliance[182]. - The company successfully held two shareholder meetings during the reporting period, with all proposed resolutions approved[184]. Financial Health and Risks - The total assets at the end of 2024 were CNY 5,204,868,837.55, a 3.14% increase from CNY 5,046,237,662.74 in 2023[26]. - The net cash flow from operating activities increased by 59.28% to CNY 406,502,236.83 from CNY 255,206,956.72 in 2023[26]. - The company reported a high accounts receivable net amount of 1,405.67 million yuan, accounting for 71.55% of current assets, indicating potential liquidity risks[97]. - The company faces risks related to clinical trial progress and potential delays in product commercialization[91][92]. - The company received a tax benefit of 13.48 million yuan as a high-tech enterprise, which may be affected by future policy changes[98]. Talent Development and Management - The company is focusing on talent development and internal control management to enhance operational efficiency and sustainability[47][48]. - The company has a research team of 133 people, accounting for 10.44% of the total workforce, with an average salary of RMB 17.01 million for R&D personnel[79]. - The company plans to attract and cultivate high-quality talent in R&D, production, and sales to support long-term development and innovation[172]. - The company will optimize its compensation and performance management system to maximize employee effectiveness and support sustainable development[178].
百克生物:多个在研产品取得关键进展 将重点进行营销业务模式升级调整
值得注意的是,近日,百克生物参股公司传信生物医药(苏州)有限公司自主研发的"新型mRNA肿瘤疫苗 TMT101"开展的一项"研究者发起的临床试验"在中国医学科学院北京协和医院顺利完成首例患者给药及 剂量限制性毒性(DLT)观察,未出现DLT事件,TMT101是传信生物自主研发的新型mRNA肿瘤疫苗,进 入体内后可由脂质纳米颗粒(LNP)递送至细胞,编码产生的肿瘤相关抗原(TAA)能够被抗原呈递细胞 (APC)有效提呈并刺激产生特异性的T细胞反应,进而达到杀伤肿瘤细胞和治疗癌症的目的,有望在"泛 癌种"治疗中发挥作用。 2024年,面对同类产品的价格调整以及新竞品获批上市等带来的挑战,百克生物紧密关注市场动态,积 极调整市场营销策略,公司与阿里健康、百度、知乎、小红书等流量平台建立合作关系,积极开发公众 号资源,借助流量平台,打通多渠道流量入口。此外,与疫苗专业平台合作,如小豆苗、约苗,结合文 章科普教育触达用户,通过精准投放实现用户转化,进而实现线上营销。线下渠道方面,通过与医院智 慧屏的合作,利用线下渠道进行精准广告投放,从而优化客户获取流程并提升转化率。 百克生物(688276)4月20日晚发布2024年 ...
百克生物(688276) - 长春百克生物科技股份公司关于召开2024年度暨2025年第一季度业绩说明会的公告
2025-04-11 07:45
证券代码:688276 证券简称:百克生物 公告编号:2025-010 长春百克生物科技股份公司 关于召开 2024 年度暨 2025 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 会议召开时间:2025 年 4 月 21 日(星期一)上午 09:00-10:00 (三)会议召开方式:上证路演中心网络互动 会议召开地点: 上海证券 交 易 所 上 证 路 演 中 心 ( 网 址 : https://roadshow.sseinfo.com/) 会议召开方式:上证路演中心网络互动 投资者可于 2025 年 4 月 14 日(星期一)至 4 月 18 日(星期五)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@bchtpharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 长春百克生物科技股份公司(以下简称"公司")将于 2025 年 4 月 21 日发 布公司 2024 年年度报告及 2025 年第一季度报告,为便于广 ...